Loading
India's second approved CAR-T therapy, a Bengaluru-made version of a Spanish hospital's academic CD19 cell therapy, for lymphoma that has come back after other treatments.
Varnimcabtagene autoleucel (var-cel) is the international nonproprietary name of ARI-0001, the CD19 CAR-T developed at Hospital Clinic de Barcelona and approved in Spain under the hospital exemption; Immuneel Therapeutics licensed it for India as IMN-003A and manufactures it at Narayana Health City in Bengaluru. Immuneel's phase 2 IMAGINE study, described as the first industry-sponsored CAR-T trial in India, treated adults with relapsed or refractory B-cell malignancies and was reported at ASH 2023 and in Hematological Oncology. On the strength of it Qartemi received CDSCO market authorisation in 2024 for relapsed or refractory B-cell lymphoma.
In Spain the same cell product has reported an 84.4% complete response with undetectable measurable residual disease by day 28 in 32 adults with relapsed B-ALL (CART19-BE-02, Lancet Haematology 2026), 100% response in follicular lymphoma and 89% in mantle cell lymphoma (HemaSphere 2025-26). Qartemi and NexCAR19 together give India two locally made CD19 CAR-Ts competing on price, something no other lower-middle-income country has.
Autologous T cells transduced with a lentiviral anti-CD19 (A3B1 scFv) CAR with 4-1BB and CD3-zeta domains; academic point-of-care design from Hospital Clinic de Barcelona. Connects to CD19.
1.Leukapheresis at the treating centre
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| IN | 2024 | Relapsed or refractory B-cell lymphoma · CDSCO market authorisation as announced by Immuneel; ARI-0001 is separately approved in Spain under the hospital exemption |
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| IN | Public insurance cover not established; ask the treating centre | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Varnimcabtagene autoleucel" OR ABSTRACT:"Varnimcabtagene autoleucel" OR TITLE:"Qartemi" OR ABSTRACT:"Qartemi" OR TITLE:"IMN-003A" OR ABSTRACT:"IMN-003A" OR TITLE:"var-cel" OR ABSTRACT:"var-cel" OR TITLE:"ARI-0001" OR ABSTRACT:"ARI-0001") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Varnimcabtagene autoleucel, not a curated reading list.
Shares Talicabtagene autoleucel, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care.
Shares Point-of-care and decentralised cell manufacturing, Talicabtagene autoleucel, Cytokine release syndrome (CRS), Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation.
Shares Point-of-care and decentralised cell manufacturing, Talicabtagene autoleucel, Manufacturing cost and time for living and radioactive medicines, CD19.
Shares Point-of-care and decentralised cell manufacturing, Talicabtagene autoleucel, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Manufacturing cost and time for living and radioactive medicines.
Shares Point-of-care and decentralised cell manufacturing, Talicabtagene autoleucel, Manufacturing cost and time for living and radioactive medicines, CD19.
Shares Tisagenlecleucel, ICANS (neurotoxicity), Cytokine release syndrome (CRS), Manufacturing cost and time for living and radioactive medicines.
Shares Tisagenlecleucel, Cytokine release syndrome (CRS), Manufacturing cost and time for living and radioactive medicines, CD19.
Shares Tisagenlecleucel, ICANS (neurotoxicity), Cytokine release syndrome (CRS), Manufacturing cost and time for living and radioactive medicines.